HighLife Medical (Irvine, Calif.) recently raised $14 million for its transcatheter mitral valve replacement. In October last year, the company’s €12.3 million round was led by European venture capital shop Soffinova Partners, as well as LivaNova.
Highlife’s two-component transcatheter mitral valve replacement system is currently an investigational device and is not yet for sale anywhere. It self-centers and self-aligns while efficiently sealing around the prosthesis to prevent paravalvular leaks from happening. The implant is one size that can fit most mitral valve regurgitation patients. It can be implanted in annuli with the largest axis starting at 35mm up to 50mm.
The transcatheter mitral valve replacement uses a ring around a valve’s leaflets. It is designed to guide a replacement valve into place and can be delivered through the inter-atrial septum instead of the trans-apical.